Pakistan: Adding pioglitazone to a treatment regimen of metformin and SGLT2 inhibitors significantly improves glycemic control and metabolic parameters in patients with diabetes. Higher-dose pioglitazone (30 mg) provides greater therapeutic benefits; however, these advantages must be weighed against predictable adverse effects, particularly weight gain. The findings highlight the need for individualized treatment decisions to optimize efficacy while minimizing side effects.

Despite the availability of multiple glucose-lowering therapies, many patients with type 2 diabetes mellitus (T2DM) fail to achieve recommended glycemic targets with dual therapy alone. Pioglitazone, an insulin-sensitizing agent, has been proposed as an additional treatment option for patients whose blood glucose remains inadequately controlled despite receiving metformin and sodium-glucose cotransporter-2 (SGLT2) inhibitors. To evaluate its effectiveness and safety, researchers performed an updated systematic review and meta-analysis of randomized controlled trials.
The study, published in the Annals of Pharmacotherapy, was led by Syed Ibad Hussain, MBBS, Jinnah Sindh Medical University, Karachi, Pakistan, and colleagues.
Researchers systematically searched PubMed, Scopus, the Cochrane Library, and Google Scholar through February 2026 for randomized controlled trials evaluating pioglitazone as a third-line therapy in adults with T2DM inadequately controlled on metformin and SGLT2 inhibitors. Four randomized controlled trials involving 1,213 participants met the inclusion criteria. Outcomes included glycemic control, insulin resistance, cardiometabolic parameters, and treatment-related adverse events.
Key Findings:
  • Adding pioglitazone to metformin and SGLT2 inhibitors reduced HbA1c by an average of 0.56% compared with standard therapy.
  • Pioglitazone more than doubled the likelihood of achieving the target HbA1c level below 7%.
  • The 30 mg dose produced greater HbA1c reductions than the 15 mg dose, demonstrating a dose-dependent effect.
  • Pioglitazone significantly improved fasting plasma glucose, insulin resistance, triglyceride levels, HDL cholesterol, and diastolic blood pressure.
  • Treatment with pioglitazone was associated with an average weight gain of 2.38 kg.
  • Pioglitazone also resulted in a higher risk of adverse drug reactions than standard therapy.
The findings suggest that the metabolic benefits of pioglitazone should be weighed against its predictable adverse effects when selecting patients for therapy.
The researchers noted that pioglitazone may be particularly beneficial for patients with persistent hyperglycemia and significant insulin resistance despite treatment with metformin and an SGLT2 inhibitor, supporting an individualized rather than routine treatment approach.
The researchers concluded that adding pioglitazone to metformin and SGLT2 inhibitor therapy significantly improves glycemic control and metabolic outcomes in type 2 diabetes. Although the 30 mg dose provides greater efficacy, its benefits should be balanced against predictable side effects, particularly weight gain, when making individualized treatment decisions.
Reference:
Hussain, S. I., Jalal, A. A., Adnan, Z., Shakir, S., Chandani, D. K., & Makhdoom, M. A. Efficacy and Safety of Pioglitazone Added to Metformin and SGLT2 Inhibitors in Type 2 Diabetes: An Updated Systematic Review and Meta-analysis. Annals of Pharmacotherapy. https://doi.org/10.1177_10600280261452484


Tags:    
Article Source : Annals of Pharmacotherapy

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .